Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease
Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease
Authors
Singulani, Monique Patricio
Ferreira, Ana Flavia Fernandes
Figueroa, Paulina Sepulveda
Cuyul Vasquez, Ivan
Talib, Leda Leme
Britto, Luiz Roberto
Forlenza, Orestes Vicente
Ferreira, Ana Flavia Fernandes
Figueroa, Paulina Sepulveda
Cuyul Vasquez, Ivan
Talib, Leda Leme
Britto, Luiz Roberto
Forlenza, Orestes Vicente
Profesor GuĆa
Authors
Date
Datos de publicaciĆ³n:
10.1016/j.arr.2024.102231
AGEING RESEARCH REVIEWS,Vol.95,2024
AGEING RESEARCH REVIEWS,Vol.95,2024
Tipo de recurso
Review
Keywords
Materia geogrƔfica
Collections
Abstract
The role of lithium as a possible therapeutic strategy for neurodegenerative diseases has generated scientific interest. We systematically reviewed and meta-analyzed pre-clinical and clinical studies that evidenced the neuroprotective effects of lithium in Alzheimer's (AD) and Parkinson's disease (PD). We followed the PRISMA guidelines and performed the systematic literature search using PubMed, EMBASE, Web of Science, and Cochrane Library. A total of 32 articles were identified. Twenty-nine studies were performed in animal models and 3 studies were performed on human samples of AD. A total of 17 preclinical studies were included in the meta-analysis. Our analysis showed that lithium treatment has neuroprotective effects in diseases. Lithium treatment reduced amyloid-beta and tau levels and significantly improved cognitive behavior in animal models of AD. Lithium increased the tyrosine hydroxylase levels and improved motor behavior in the PD model. Despite fewer clinical studies on these aspects, we evidenced the positive effects of lithium in AD patients. This study lends further support to the idea of lithium's therapeutic potential in neurodegenerative diseases.